AKBA vs PATH · rev $160.2M vs P/E 19, rev $1.61B
Akebia Ther (AKBA) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Akebia Ther (AKBA) is a drug manufacturers - specialty & generic company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported AKBA revenue for 2024-12-31 was $160.2M. Net income was -$69.4M. Revenue was down 17.7% from 2023-12-31 to 2024-12-31. AKBA currently screens at market cap $260.1M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
AKBA currently screens at market cap $260.1M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the AKBA and PATH stock pages for the full models.
Not investment advice.